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The generation of high-affinity antibodies depends on somatic hypermutation (SHM).
SHM is initiated by the activation-induced cytidine deaminase (AID), which generates
uracil (U) lesions in the B-cell receptor (BCR) encoding genes. Error-prone processing
of U lesions creates a typical spectrum of point mutations during SHM. The aim of this
study was to determine the molecular mechanism of SHM in humans; currently available
knowledge is limited by the number of mutations analyzed per patient. We collected a
unique cohort of 10 well-defined patients with bi-allelic mutations in genes involved in
base excision repair (BER) (UNG) or mismatch repair (MMR) (MSH2, MSH6, or PMS2)
and are the first to present next-generation sequencing (NGS) data of the BCR, allowing
us to study SHM extensively in humans. Analysis using ARGalaxy revealed selective
skewing of SHM mutation patterns specific for each genetic defect, which are in line
with the five-pathway model of SHM that was recently proposed based on mice data.
However, trans-species comparison revealed differences in the role of PMS2 and MSH2
in strand targeting between mice and man. In conclusion, our results indicate a role for
UNG, MSH2, MSH6, and PMS2 in the generation of SHM in humans comparable to their
function in mice. However, we observed differences in strand targeting between humans
and mice, emphasizing the importance of studying molecular mechanisms in a human
setting. The here developed method combining NGS and ARGalaxy analysis of BCR
mutation data forms the basis for efficient SHM analyses of other immune deficiencies.
Keywords: B cells, somatic hypermutation, DNA repair, mismatch repair (MMR), base excision repair (BER),
immunoglobulin, B-cell receptor, constitutional mismatch repair deficiency (CMMRD)
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KEY POINTS
- Patients with MMR or UNG deficiency have reduced
frequency and altered patterns of SHM in line with a five-
pathway model to generate SHM.
- Trans-species comparison identifies differences in strand
targeting of SHM between man and mice.
INTRODUCTION
The formation of high-affinity antibodies is based on the efficient
introduction of somatic point mutations in the variable region
of the B-cell receptor (BCR) encoding genes. Initiation of
these somatic hypermutations (SHM) requires the activity of
activation-induced cytidine deaminase (AID) that deaminates
cytosines (C) to uracils (U), thereby generating highly mutagenic
U lesions (1, 2). Establishing mutations at or around the
initial U lesion requires error-prone processing involving the
activity of the conventional DNA repair proteins uracil-DNA-
glycosylase (UNG) and proteins from the mismatch repair
(MMR) pathways (3).
Mutations in UNG are very rare and cause the
immunodeficiency hyper-IgM type 5 (OMIM #608106). Due to a
defect in class switch recombination (CSR), these patients mainly
produce IgM, leading to recurrent opportunistic infections. In
contrast, bi-allelic mutations in MMR result in constitutional
mismatch repair deficiency (CMMRD) (OMIM #276300). This is
a rare childhood cancer predisposition syndrome without overt
clinical signs of an immunodeficiency (4).
To determine the role of UNG and MMR in SHM, knock-out
and knock-in mice with defined mutations in these genes have
been used. Thereby, three main pathways have been identified to
resolve the U lesions introduced by AID (5, 6). First, if B cells
replicate before resolving the U lesion, the U is recognized as
a template T by the replicative polymerases resulting in C>T
and G>A transitions. Second, the base excision repair (BER)
enzyme Ung removes the U generating an apyrimidinic site (AP)
(7). Upon subsequent cell division, translesion synthesis (TLS)
polymerases including Rev1 are recruited, which can bypass
AP sites (8). Since AP sites are non-instructive, any nucleotide
can be inserted across from them, resulting in transitions and
transversions at GC base pairs. Third, the U lesion can be
recognized as a U:G mismatch by the MMR binding complex
Msh2/Msh6, leading to the activation of exonuclease 1 (Exo1),
which removes a stretch of nucleotides leaving a single-strand
DNA gap (9, 10). Subsequently, site-specific monoubiquitination
of proliferating cell nuclear antigen at lysine 164 (PCNA-Ub)
facilitates a polymerase switch from a replicative polymerase
(POLD or POLE) to POLH, which preferentially inserts
mismatched nucleotides opposite T nucleotides specifically at
WA/TWmotifs (8, 11–17).
More recently, the existence of a fourth Ung+Msh2 hybrid
pathway was proposed, which requires both the single-strand
gap generation by Msh2/Msh6 and the AP generation by Ung
(8, 10). In this pathway the U:G mismatch is recognized by
the Msh2/Msh6 complex, and a single-strand gap is created by
Exo1. If, however, on the opposite strand an AP site is created
by Ung, TLS can insert a base opposite of the AP site resulting
in transversions at template CG base pairs (18). Additionally,
a fifth long patch BER pathway has been proposed, which
is independent of Msh2, but dependent on Ung, PCNA-Ub,
and POLH and accounts for 10–20% of mutations at AT base
pairs (5, 14).
Although, a lot is known about the mechanism of SHM in
mice, it is still not completely clear what the roles of Pms2 and
Mlh1 are in SHM. They were long thought to be dispensable for
SHM (19–23); however, a recent publication by Girelli Zubani
et al. showed that Ung/Pms2 double knockout mice have a 50%
reduction in the number of mutations at AT base pairs (24). They
suggest that the Pms2/Mlh1 complex provides the nick required
for AT mutagenesis and that in the absence of the Pms2/Mlh1
complex, Ung can compensate for its function.
Virtually all studies that focused on elucidating the molecular
mechanism of SHM were performed in mice. Very few studies
have been able to study the role of UNG and MMR proteins
in SHM in humans as deficiencies in UNG or MMR are very
rare. So far, three studies have been able to analyze the SHM
spectrum in the VH3-23 region of IGHM transcripts of purified
CD19+CD27+ B cells using Sanger sequencing in humanMSH6
deficiency (four patients, mean: 103 mutations), UNG deficiency
(two patients, mean: 119 mutations), or PMS2 deficiency (two
patients; 65 mutations on average) (25–27). In this study,
we have been able to collect a unique cohort of 10 patients
carrying bi-allelic mutations in UNG, MSH2, MSH6, or PMS2.
In these patients, we performed next-generation sequencing
(NGS) of the BCR heavy chain (IGHG and IGHA transcripts),
allowing more in-depth analysis (mean 2,842 mutations per
patient). The obtained data set allowed us to test if and to
what extent the SHM models described above are applicable to
humans. Furthermore, we compared our results to published
results from different knockout mouse models and patients.
These trans-species comparisons provided the first insights into
differential activities of defined mutator pathways in establishing
the mutation spectra.
METHODS
Healthy Controls and Patients
Peripheral blood samples were collected from one MSH2
patient, three MSH6 patients, five PMS2 patients, and one
UNG patient (Table 1). From the UNG-deficient and the
MSH2-deficient patient, peripheral blood was obtained with
informed consent according to the guidelines of the Medical
Ethics Committees of the Erasmus MC. From patient MSH6-
01 and PMS2-05, frozen PBMCs were obtained from the Dutch
Childhood Oncology group (DCOG or SKION in Dutch) from
project number OC2016-009. The remainder of the patients were
recruited via the network of human geneticists and (pediatric)
oncologists working throughout Europe and theMiddle East who
were informed about the study at conferences and via personal
communication from 2014 to 2017. Most of participating
physicians were partners of the consortium “Care for CMMRD
(C4CMMRD)” (4). This study was performed in compliance with
current guidelines for good clinical practice and the Declaration
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TABLE 1 | Characteristics and B cell levels of the CMMRD- and UNG-deficient patients.
Patient code Study number (4) Age range in years Gene Mutations CD19/µla CD19+/CD27+/IgD–
(csBm) %Ba
MSH2-01 4–5 MSH2 c.1147C > T (p.R383X);
large deletion including MSH2
860
(700–1,300)
0.5
(3.9–16.2)
MSH6-01 11–18 MSH6 c.651dupT (p.K218X);
c.3957dupA (p.A1320SfsX5)
MSH6-02 (4) 13 6–10 MSH6 c.1135_1139delAGAGA (p.R379X);
c.2277_2293del (p.E760PfsX6)
195
(300–500)
2.26
(3.85–16.5)
MSH6-03 (4) 14 6–10 MSH6 c.2238dupT (p.L747SfsX9);
c.2980T > A (p.Y994N)
582
(300–500)
5.54
(3.85–16.5)
PMS2-01 (4, 28) 15 11–18 PMS2 c.2007-2A > G;§
c.2007-2A > G
168.5
(300–500)
5.37
(4–22.8)
PMS2-02 (4, 29) 11 6–10 PMS2 c.2444C > T (p.S815L);
c.2444C > T (p.S815L)
548
(300–500)
4.52
(3.85–16.5)
PMS2-03 (4) 5 6–10 PMS2 c.634C > T (p.Q212X);
c.1239del (p.D414TfsX34)
193
(300–500)
9.88
(3.85–16.5)
PMS2-04 (4) 16 6–10 PMS2 c.1145-31_1145-13del;§§
c.1145-31_1145-13del
213
(300–500)
10.47
(4–22.8)
PMS2-05 11–18 PMS2 c.943C > T (p.R315X);
c.943C > T (p.R315X)
UNG02 19–61 UNG c.392delC (p.P131HfsX13);
c.392delC (p.P131HfsX13)
200
(300–500)
0.7
(6.5–29.1)
§ In a different patient, it was shown that the mutation c.2007-2A > G leads to the following two aberrant transcripts: r.2007_2023del (p.S669RfsX9) and
r.2007_2174del (p.S669_A725delinsR).
§§cDNA sequencing showed two aberrant transcripts: r.1144_1145insGATAGTCCACGTTTGCTTAG (p.N383X) and r.1145_2006del (p.G382VfsX19).
a Reference values are indicated in brackets and were taken from Huck et al. (30) for the age groups 4–5 years, 6–10 years, and 11–18 years; and from Warnatz and Schlesier (31) for
the age group 19–61 years.
of Helsinki with an IRB approval (29-178 ex 16/17) from the
Medical University Graz (IRB00002556). Data of the included
age-matched HCs have been previously published by IJspeert
et al. (32) (see Supplemental Table 1).
Repertoire Sequencing Using NGS
PBMCs were isolated from peripheral blood samples using Ficoll.
For analysis of the antigen-selected BCR repertoire, mRNA was
isolated from total PBMCs using the Gen-Elute Mammalian
total RNA miniprep kit from Sigma-Aldrich (St. Louis, MO).
The cDNA libraries were derived from 2 µg of RNA using the
Superscript II reverse transcriptase kit from Invitrogen (Paisley,
UK). IGH rearrangements were amplified in a multiplex PCR
using the forward VH1-6 FR1 (BIOMED-2) primers and either
the CgCH1 or the IGHA reverse primer (33–35). Afterwards,
PCR products were purified and sequenced using Roche 454
sequencing as previously described (36). In short, PCR products
were purified by gel extraction (Qiagen, Valencia, CA) and
Agencourt AMPure XP beads (Beckman Coulter, Fullerton, CA).
Subsequently, PCR products were quantified using the Quant-it
Picogreen dsDNA assay (Invitrogen, Carlsbad, CA). The purified
PCR products were sequenced on the 454 GS junior instrument
using the Lib-A or Lib-A V2 kits. For one patient, 100 ng of DNA
was used to amplify VH-JH rearrangements using VH1-6 FR1
forward primers (BIOMED-2) and JH consensus reverse primers
(33). The PCR product was purified and sequenced as described
above. This patient (PMS2-01) was excluded from the analyses of
subclass distribution as no information on the constant domain
can be obtained using this approach. In addition, this patient
is not included in the calculation of the percentage SHM as,
in contrast to the other patients and the HCs, the sequences
obtained from this patient are not selected for IGHA and IGHG
and therefore also contain all sequences from naïve and/or non-
switched cells thereby greatly influencing SHM levels.
Immune Repertoire Data Analysis
Sequences were demultiplexed based on their multiplex identifier
sequence and trimmed from both sides (40 nt for sequences
obtained from RNA and 30 nt for the sequences obtained from
DNA) to remove the primer sequence using ARGalaxy (37).
Fasta files were uploaded in IMGT/High-V-Quest (version 1.5.6)
(38), and subsequently the IMGT output files were analyzed
using ARGalaxy (37). Here, incomplete sequences or sequences
containing an ambiguous “n” base were excluded. To remove
sequencing errors, only sequences of which the exact sequence
was present at least twice were included. Afterwards, any
duplicate sequences were removed. Due to high clonal relation
of the sequences in a subgroup of patients, which could lead to
major skewing in SHM patterns, only one sequence per clone
(based on V-gene and maximal 3-nt difference within the CDR3
using Change-O) (32, 39) was included in further analysis. From
the filtered sequences, information on mutation patterns and
targeting motifs were obtained. For the analysis of SHM levels
and subclass distribution, one sequence per clone based on Class,
V-gene, and maximal 3-nt difference within the CDR3 using
Change-O (39) was included and results were split into IGHA
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and IGHG as it is known that these parameters differ between
these classes (32). All HC samples were re-analyzed using the
same analysis settings. The number of reads after filtering and
the number and patterns of mutations (transition tables) can
be found in Supplemental Table 1. Samples containing a low
number of reads for either IGHA or IGHG after filtering (<45)
were excluded from the analysis of SHM levels and subclass
distribution (Supplemental Table 1). All calculations used for
Figures 1–4 can be found in the Supplemental Methods.
Literature Search
On the 19th of March 2018, we search PubMed for
publications on Ung, Msh2, Msh6, and Pms2 deficiency
in mice and humans using the following search criteria:
(((((msh2[Title/Abstract]) OR msh6[Title/Abstract])
OR pms2[Title/Abstract]) OR mlh1[Title/Abstract]) OR
UNG[Title/Abstract]) AND (shm[Title/Abstract] OR somatic
hypermutation[Title/Abstract]). We excluded reviews,
publications without transition tables or information about
the nucleotide composition of the sequenced region, and
publications in which the SHM was measured in cell lines or
in the switch regions. Eight publications matched these criteria
(8, 18, 19, 21, 24, 40–42). In addition, we received a transition
table on three of the four MSH6 patients from the Gardes et al.
publication, which were also included in the analysis (26). The
publications on the UNG-, MSH6, and PMS2-deficient patients
did not contain information on the nucleotide composition of
the sequenced region (25, 27). In both publications, only the
IGHV3-23 gene was analyzed for SHM; therefore, we calculated
the nucleotide composition of the VH3-23 (FR1–FR3) region
ourselves (21% A, 22% T, 25% C, 32% G) and included these in
the analysis. For calculations of the number of transversions at
GC base pairs, the number of mutations at AT base pairs, and
the A/T ratio, we corrected the number of mutations for the
nucleotide composition because most publications sequenced a
different genomic region to analyze SHM. An overview of the
publications and data used to calculate the mutations can be
found in Supplemental Table 2.
Data Visualization and Statistics
Plots were made using GraphPad Prism V7.0, and statistics on
these plots were done using the same software.
RESULTS
Patients With BER and MMR Deficiency
Have Reduced Frequency of SHM and
Altered Subclass Usage
To study the molecular mechanism of SHM in human, we
included a unique cohort of 10 patients with UNG, MSH2,
MSH6, or PMS2 deficiency, and 15 previously published age-
matched HCs (Table 1) (32). Since the amount of blood that was
available for most of the patients was very limited, we decided to
analyze the IGHA and IGHG rearrangements from total PBMCs.
These rearrangements are derived from antigen-experienced B
cells that have undergone CSR and SHM. For the majority of
patients (n = 8), we were able to analyze both IGHA and IGHG
rearrangements. For the MSH2- and UNG-deficient patients,
<45 IGHG (UNG) or IGHA (MSH2) sequences were obtained,
and therefore these samples were excluded from the analysis
of the SHM frequency or subclass distribution of this class.
From one PMS2 patient (PMS2-01), only DNA from PBMCs was
available; therefore, we sequenced the IGH rearrangements on
the DNA level precluding subclass assignment and the analysis
of SHM levels.
Recently, we have shown that patients with CMMRD have
no overt clinical immunodeficiency (4). In this study, we were
able to include data from three additional CMMRD patients. In
line with the study of Tesch et al. the frequency of SHM was
reduced in both IGHG and IGHA rearrangements, except for one
of the MSH6-deficient patients (MSH6-01) in which SHM was
within the normal range for IGHG rearrangements (Figure 1A).
Despite the fact that the frequency of switch memory B cells
was within the normal range in most of the patients (Table 1),
the distribution of the IGHG and IGHA subclasses was different
in the CMMRD- and UNG-deficient patients. They had an
increased frequency of IGHG3, IGHG1, and IGHA1 compared to
the HCs (Figures 1B,C). Thus, although patients with CMMRD
have no clinical signs of immunodeficiency, molecular analysis of
the BCR rearrangements shows clear aberrancies.
Analysis of SHM in UNG- and
MMR-Deficient Patients Shows Evidence
for Five SHM Pathways in Human
According to current models based on knockout mice, Ung is
crucial in generating transversions at GC base pairs and the
Msh2/Msh6 complex is necessary to generate mutations at AT
base pairs. In line with this model, the UNG-deficient patient
had a∼4.5-fold decrease in the frequency of transversions at GC
base pairs (Figures 2A,B, Supplemental Table 1). In addition,
the MSH2- and MSH6-deficient patients had an almost threefold
decrease in the frequency of mutations at AT base pairs and
WA/TW motifs, suggesting that ∼65% of the AT mutations
areMSH2/MSH6 dependent (Figures 2A,C,D). Additionally, the
MSH2- andMSH6-deficient patients had a significant increase in
the frequency of mutations in RGYW/WRCYmotifs, confirming
that the MSH2/MSH6-dependent pathway creates mutations
outside RGYW/WRCY motifs (Figure 2E).
In line with the five-pathway model, we also observed ∼35%
less mutations at AT base pairs and WA/TWmotifs in the UNG-
deficient patient (Figures 2A,C,D), suggesting that, in humans,
UNG is necessary to create the remaining∼35% of the mutations
at AT base pairs. The MSH2- and MSH6-deficient patients
also had a small but significant decrease in the frequency of
mutations at GC base pairs that are transversions (Figures 1A,B),
confirming that in humans, the MSH2/MSH6 complex is also
necessary to generate∼25% of the transversions at GC base pairs,
possibly via the proposed UNG/MSH2 hybrid pathway. Details
on the number of bases sequences and the number of mutations
can be found in Supplemental Table 1.
To get more insight into the absolute changes, we also
analyzed the absolute mutation frequency (mutations/number of
sequenced AT or CG bases). This revealed that UNG deficiency
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FIGURE 1 | Mutations in MMR and BER proteins lead to reduced frequency of SHM. (A) Median SHM frequency in IGHG and IGHA rearrangements is reduced in
UNG-, MSH2-, MSH6-, and PMS2-deficient patients compared to HCs. Frequency of IGHG (B) and IGHA subclasses (C). Patients with UNG-, MSH2-, MSH6-, and
PMS2-deficiency have more IGG1, IGG3, and IGA1 rearrangements compared to HCs. Statistical significance was performed using a Mann–Whitney test and
indicated using *P < 0.05 and **P < 0.01.
leads not only to a strong reduction in transversions at GC
base pairs but also to a reduction of the mutations at AT base
pairs (Figure 2F), confirming the role of UNG in generation
GC transversions and a minority of AT mutations. The absolute
number of GC transitions was increased in the UNG-deficient
patient, suggesting that in the absence of UNG, more U lesions
persist and serve as a template for DNA synthesis.
In the MSH2- and MSH6-deficient patients, the absolute
number of mutations at AT base pairs was significantly
reduced (Figure 2F), which also explains at least part of the
reduced frequency of SHM since almost half of all mutations
locate at AT base pairs. Furthermore, a significant reduction
in the absolute number of GC transversions was observed
in these patients, indicating a critical contribution of the
mismatch recognition complex MSH2/MSH6 in generating GC
transversions. Altogether, these data show that in humans the
U:G mismatches can be resolved via direct DNA synthesis across
U, UNG-dependent short patch BER pathway, the UNG/POLH-
dependent long-patch BER pathway, the UNG-independent
MSH2/MSH6-dependent pathway, and the UNG/MSH2
hybrid pathway.
The Role of PMS2 in SHM
Pms2 has long been thought to be dispensable for SHM in mice.
Also, in two patients with PMS2 deficiency, no differences in the
mutation spectrumwere reported (27). In this study, we were able
to study 254–1,388 unique IGH rearrangements per patient in
a total of five PMHS2-deficient patients. In the single previous
study, only two PMS2-deficient patients and seven unique B cell
clones could be studied (27). The increased sequencing depth
revealed clear differences in the mutation spectrum. The PMS2-
deficient patients had a∼1.2-fold decrease in the frequency of AT
mutations and mutations in TW/WA motifs (Figures 2A,C,D).
Furthermore, they had a ∼10% decrease in transversions at GC
base pairs, and a ∼1.2-fold increased frequency of mutations
in RGYW/WRCY motifs (Figures 2B,E). This was in line with
the trends found in the MSH2- and MSH6-deficient patients,
although the differences were much milder. The absolute
mutation frequency pattern is different in the PMS2-deficient
patients compared to the MSH2- and MSH6-deficient patients
(Figure 2F). The mutation pattern from PMS2-deficient patients
showed a reduction in the number of AT mutations (68%) and
transversions at GC base pairs (56%), but they also revealed a
decrease in the number of GC transitions (53%). Altogether, these
data indicate that PMS2 contributes to the error-prone resolution
of U:G mismatches in humans, although its exact role remains to
be determined.
PMS2, MSH2, and MSH6 Deficiency Result
in an Altered A-Over-T Mutation Ratio
The ratio between mutated A’s and T’s gives information about
the targeting of the non-transcribed vs. the transcribed strand
as PPOLH has in intrinsic T over A mutation bias (a four
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FIGURE 2 | UNG and MMR deficiency result in changes in SHM patterns. (A) Transition tables of HCs, UNG-, MSH2-, MSH6-, and PMS2-deficient patients. The
percentage of mutations at GC base pairs that are transversions (B) and the percentage of mutations at AT base pairs (C) in HCs and UNG-, MSH2-, MSH6-, and
PMS2-deficient patients. The percentage of SHM present in WA/TW (D) and RGYW/WRCY motifs (E) in HCs and patients with genetic defects in MMR or BER.
(F) Absolute frequency of mutations at AT base pairs and transitions and transversions at GC base pairs as compared to age-matched controls (n = 5 for age 3–4
and n = 10 for age 6–22). Statistical significance was performed using a Mann–Whitney test and indicated using *P < 0.05, **P < 0.01, and ***P < 0.001.
times higher mutation frequency when copying T’s then A’s.
Because the number of sequenced A’s and T’s in our data was
not exactly the same (24.7–25.9% A’s, 20.8–21.5% T’s), we first
corrected the number of mutations at A’s and T’s for the number
of sequenced A’s and T’s to calculate the A/T ratio (Figure 3A,
Supplemental Methods). In the HCs, the average A/T ratio
was 1.7 (range 1.5–2) (Figure 3B), indicating that the non-
transcribed strand ismutated∼3 timesmore than the transcribed
strand, leading to a 3:1 strand bias (24, 43).
The A/T ratio in the UNG-deficient patient was not different
from the HCs (Figure 3B) (24). However, in the MMR-deficient
patients, the A/T ratio was significantly decreased (Figure 3B).
The average A/T ratio in the MSH2- and MSH6-deficient
patients was 1.2 (range 1–1.2), which corresponds to a 3:2
ratio of error-prone repair by POLH on the non-transcribed
vs. the transcribed strand. This suggests that in the absence of
the MSH2/MSH6 complex, the A/T bias is almost lost and
error-prone repair at AT pairs is more skewed
toward the transcribed strand. The PMS2-deficient
patients had a decreased A/T ratio of 1.5 (range 1.4–
1.5), indicating a 2:1 bias of mutations toward the
non-transcribed strand.
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FIGURE 3 | Defects in UNG, MSH2, MSH6, and PMS2 influence the corrected A/T ratio. (A) Transition tables of the percentage of mutations corrected for the A,C,T,
and G content of the sequenced transcripts. (B) The corrected A/T ratio in HCs and patients with genetic defects in UNG, MSH2, MSH6, and PMS2. Statistical
significance was performed using a Mann–Whitney test and indicated using **P < 0.01.
Mutation Spectrum of Human and Mice
Indicates Differences in Strand Targeting
To check how conserved the molecular mechanism of SHM
is, we decided to perform a trans-species comparison between
our human data and previously published data on Ung,
Msh2, Msh6, and Pms2 knockout mice, and the data on the
previously published UNG- and PMS2-deficient patients. Eleven
publications in which transition tables and information on the
nucleotide composition of the sequenced region were present
(see Methods for details) were included (8, 18, 19, 21, 24–
27, 40–42). The frequency of transversions at GC base pairs was
comparable between human and mice in both the control and
the UNG-deficient patients (Figure 3A). However, the number
of transversions seemed slightly lower in the Msh2, Msh6, and
Pms2 knockout mice, compared to the patients (Figure 4A).
Interestingly, the average frequency of mutations at AT base
pairs was significantly lower in the human controls compared
to the wild-type mice (42 and 54%, respectively) (Figure 4B).
This suggest that, in mice, more U:G mismatches are resolved
by the MSH2/MSH6/EXO1 and the UNG/POLH pathways. The
frequency of mutations at AT base pairs was lower in the
UNG-deficient patients compared to the Ung knockout mice, but
likely relates to an overall decreased mutation frequency at AT
base pairs in humans. The reduction of mutations at AT base
pairs in the MSH2-, MSH6-, and PMS2-deficient patients was
comparable to the knockout mice, suggesting that the role of
these proteins is similar in human and mice. The A/T ratio in
the human controls was slightly lower compared to wild-type
mice (median 1.7 vs. 1.9), while the UNG-deficient patients and
mice had a similar A/T ratio (Figure 4C). In contrast, major
differences are found in the A/T ratio between the MSH2-
and PMS2-deficient patients and Msh2 and Pms2 knock-out
mice (24, 43). In summary, these trans-species comparison
identified differences in strand targeting of SHM between man
and mice, although more research needs to done to understand
the exact mechanism.
DISCUSSION
The induction of SHM in the BCR genes is essential to create
high-affinity antibodies. Until now, the molecular mechanism of
SHM was mainly studied using mouse models. The studies in
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FIGURE 4 | Minor differences are found in SHM patterns between mice and human. Differences in the percentage of GC mutations that are transversions (A), the
percentage mutations at AT base pairs (B), and the A/T ratio (C) between mice and human with and without genetic defects in genes involved in BER or MMR.
Statistical significance was performed using a Mann–Whitney test and indicated using *P < 0.05.
humans were very limited because of the rarity of the patients,
and the number of unique rearrangements that could be studied
was very low. This study is the first of its kind in which a unique
cohort of patients with rare diseases affecting DNA repair are
combined and analyzed using high-throughput sequencing of the
BCR rearrangements.
UNG deficiency results in an immunodeficiency, but patients
with CMMRD do not have an overt immunodeficiency (4).
Still, most of the CMMRD patients have reduced absolute
numbers of B cells (Table 1). Interestingly, the frequency of
SHMwas reduced in virtually all patients. The absolute mutation
frequencies (Figure 2F) showed that this reduction in SHM was
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mostly caused by a reduction of the mutations at AT base pairs,
which account for almost half of the SHM, and a reduction
of transversion mutations at GC base pairs. The transition
mutations at GC base pairs remained the same in the MSH2 and
MSH6 patients, suggesting that the replication pathway does not
compensate for the loss of the MMR proteins.
The number of switch memory B cells was normal in most of
the patients (Table 1); however, the frequency of IGHG3, IGHG1,
and IGHA1 was increased in the CMMRD- and UNG-deficient
patients (Figure 1). These rearrangements contain constant
genes that are closest to the VDJ exon and arise more frequently
from direct switching compared to themore downstream-located
constant genes (44). Increased usage of these proximal constant
genes can be related to a defect in CSR as switching to the
more downstream-located constant genes often requires multiple
recombination events. This can have different causes, like a
disturbed B–T cell interaction, a proliferation defect, as well
as defects in CSR itself. Mouse studies have shown a role for
UNG and MMR in CSR (5), but from our data alone, it is
impossible to determine the underlying cause of the altered
subclass distribution observed (42).
Our human data are in line with a five-pathway model to
resolve the U lesion introduced by AID (Figure 5) (5, 6, 8,
10, 14, 18). First, if the cell uses the U as a template during
replication, the incorporated U is recognized as a T, therefore
creating C>T and G>A transitions (Figure 5I). Second, the U
can be recognized and removed by UNG, leaving an AP site.
During subsequent cell divisions, this AP site is non-instructive,
leading to the recruitment of TLS polymerases, including (based
on mouse data) REV1 (45), which bypasses the AP site by
incorporating a random nucleotide or selectively a C in the case
of REV1. This leads to both transitions and transversions at GC
base pairs (Figure 5II). Third, our data indicate the presence of
a second UNG-dependent pathway in which POLH is involved,
which leads to mutations at AT base pairs and therefore is
likely based on long-patch BER as the initial lesions lie upstream
(Figure 5III). Fourth, if the U:G mismatch is recognized by the
MSH2/MSH6 dimer, a stretch of nucleotides surrounding the
mismatch is removed by most likely EXO1 (based on mouse
models), leaving a single-strand DNA gap. Consecutively, this
gap is filled by POLH, which preferentially introduces errors
at AT base pairs (Figure 5IV). The fifth and final pathway is
FIGURE 5 | Model of the molecular mechanism of SHM in human. SHM is initiated by AID, which creates a U:G mismatch and can lead to mutations via five different
routes. (I) During replication, the U can be recognized as a T leading to C>T and G>A transversions. (II) The U can be recognized and removed by UNG, creating an
AP site. During subsequent cell division, this AP site is non-instructive and therefore TLS polymerases incorporate a random nucleotide at this position leading to
transition and transversions at GC base pairs. (III) A second UNG-dependent pathway involving POLH can be initiated and lead to mutations at AT base pairs. (IV) If
the U:G mismatch is recognized by the MSH2/MSH6 dimer, multiple bases surrounding the U:G mismatch can be removed by EXO1, creating a single-strand gap.
Next, PCNA is polyubiquitinated and recruits POLH to fill this gap, thereby creating mutations at AT base pairs. (V) Finally, the MSH2/MSH6-, UNG-hybrid pathway can
be initiated with two U’s that are present in close proximity to each other but on opposing strands. Here, one of the U’s is recognized by MSH2/MSH6 and processed
to create a single-strand gap. The other U is processed by UNG, thereby creating an AP site opposite of the single-stranded gap. Next, when the single-stranded gap
is filled, a TLS polymerase is recruited to fill the gap opposing the AP site, thereby leading to MSH2/MSH6-dependent transversions at GC base pairs.
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dependent on both MSH2/MSH6 and UNG and requires at least
two U’s on opposing strands in close proximity. On one strand,
the U is processed by MSH2/MSH6 and a single-strand gap
surrounding the mismatch is created most likely by EXO1 (based
on mouse data). If, on the opposing strand, the U is excised by
UNG and an AP site is created, TLS polymerases including REV1
(based on mouse data) can bypass the abasic site, while creating
transversions and transitions at the AP site (Figure 5V).
The role of PMS2 during SHM is still not completely clear.
Recently, Girelli Zubani et al. showed that Ung/Pms2 double
knockout mice have a 50% reduction in the number of mutations
at AT base pairs (24). They suggest that the Pms2/Mlh1 complex
provides the nick required for AT mutagenesis, and that in the
absence of the Pms2/Mlh1 complex, Ung can compensate for
its function. In this study, we showed that PMS2 deficiency in
humans also leads to a reduction of mutations at AT base pairs,
as well as to the number of transversion mutations at GC base
pairs (Figure 2). Since MSH2 and MSH6 are involved in the
hybrid pathway, which results in transversion mutations at GC
base pairs, it is tempting to speculate that PMS2 also provides the
nick in this fifth pathway (Figure 5). Unfortunately, we were not
able to analyze cells from patients with MLH1 deficiency, but it
would be very interesting to see if they display the same changes
in SHM patterns as the PMS2-deficient patients.
The PMS2-deficient patients had a decreased A/T ratio of
1.5 (range 1.4–1.5), which is in contrast to earlier findings in
Pms2 knockout mice in which an A/T ratio of 4 was reported
(24, 43). This would suggest that in the PMS2-deficient patient,
error-prone repair is skewed toward the transcribed strand (2:1),
while the A/T ratio in mice suggests that the error-prone repair is
solely found on the non-transcribed strand. Based on the mouse
data, Girelli Zubani et al. have proposed that Pms2/Mlh1 has no
strand bias in nick creation and that the strand bias found in wt
mouse is the result of other glycosylases only targeting the non-
transcribed strand. The reduction in A/T ratio in PMS2 patients
found in this study does not comply with the sole targeting of the
other glycosylases toward the non-transcribed stand. In contrast,
our data show that in the absence of PMS2, AT mutations are
more skewed toward the transcribed strand (from 3:1 to 2:1).
In addition, the reduction of the A/T ratio is also in contrast
with the proposed equal targeting of both strands by PMS2.
This discrepancy can be due to the fact that the PMS2-deficient
patients might have some residual PMS2 activity. However, four
out of the five PMS2 mutations lead to premature stop codons
(Table 1), and even though the patients have different mutations,
the results were exactly the same for all patients. Therefore, it
is likely that the role of PMS2 in mice and humans is slightly
different during SHM.
In conclusion, this study is the first to apply NGS on a
cohort of genetically well-defined patients suffering from rare
genetic defects in UNG and MMR. The results obtained in
this unique cohort are most compatible with the five-pathway
model for the mechanism of SHM based on human data. In
addition, our data indicate differences in the role of MSH2
and PMS2 in strand targeting of SHM between mice and
man. Our findings emphasize the importance of confirmation
of findings in mice in a human setting. Moreover, the here
developed method combining NGS and ARGalaxy analysis of
BCR mutation data forms the basis for efficient SHM analyses
of other related deficiencies.
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